FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938369148> ?p ?o ?g. }

• W2938369148 endingPage "1276" @default.
• W2938369148 startingPage "1266" @default.
• W2938369148 abstract "IntroductionROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS).Patients and MethodsThe trial was a multicenter, single-arm phase II trial (Clinicaltrial.gov identifier: NCT02183870). Key eligibility criteria included patients who were 18 years of age or older with advanced/metastatic lung cancer and centrally confirmed ROS1-rearranged lung cancer (fluorescence-in situ hybridization). Treatment included 250 mg crizotinib twice daily. The primary endpoint was investigator-assessed objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors, version 1.1). Key secondary endpoints were progression-free survival (PFS), overall survival, efficacy by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue.ResultsThirty-four patients received treatment. Four patients were excluded from efficacy analysis. Investigator ORR was 70% (95% confidence interval [CI]: 51–85; 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1–not reached). Two patients with ROS1 wild-type sequences assessed by DNA sequencing had progression as best response. CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. TP53-co-mutant patients had a significantly shorter median PFS than wild-type patients (7.0 months, 95% CI: 1.7–20.0 versus 24.1 months, 95% CI: 10.1–not reached; p = 0.022). Treatment-related adverse events were documented in 33 of 34 patients (97%).ConclusionsCrizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer. ROS1-/TP53-co-aberrant patients had a significantly worse outcome compared to TP53 wild-type patients." @default.
• W2938369148 created "2019-04-25" @default.
• W2938369148 creator A5000668683 @default.
• W2938369148 creator A5002306737 @default.
• W2938369148 creator A5006712577 @default.
• W2938369148 creator A5007155024 @default.
• W2938369148 creator A5008015466 @default.
• W2938369148 creator A5013884017 @default.
• W2938369148 creator A5014324672 @default.
• W2938369148 creator A5014839908 @default.
• W2938369148 creator A5016567527 @default.
• W2938369148 creator A5016904876 @default.
• W2938369148 creator A5017328208 @default.
• W2938369148 creator A5025511599 @default.
• W2938369148 creator A5026909873 @default.
• W2938369148 creator A5027301625 @default.
• W2938369148 creator A5028302880 @default.
• W2938369148 creator A5029761367 @default.
• W2938369148 creator A5032769915 @default.
• W2938369148 creator A5037915780 @default.
• W2938369148 creator A5038984237 @default.
• W2938369148 creator A5040894422 @default.
• W2938369148 creator A5044887899 @default.
• W2938369148 creator A5046639150 @default.
• W2938369148 creator A5046728958 @default.
• W2938369148 creator A5047435894 @default.
• W2938369148 creator A5055278162 @default.
• W2938369148 creator A5055554326 @default.
• W2938369148 creator A5056803492 @default.
• W2938369148 creator A5057543920 @default.
• W2938369148 creator A5058243253 @default.
• W2938369148 creator A5066952204 @default.
• W2938369148 creator A5076651124 @default.
• W2938369148 creator A5077495488 @default.
• W2938369148 creator A5080059818 @default.
• W2938369148 creator A5082092472 @default.
• W2938369148 creator A5082589698 @default.
• W2938369148 creator A5084359163 @default.
• W2938369148 creator A5085499011 @default.
• W2938369148 creator A5088140147 @default.
• W2938369148 creator A5091281351 @default.
• W2938369148 date "2019-07-01" @default.
• W2938369148 modified "2023-10-18" @default.
• W2938369148 title "Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial" @default.
• W2938369148 cites W1515180961 @default.
• W2938369148 cites W1666785645 @default.
• W2938369148 cites W1990626198 @default.
• W2938369148 cites W2019607817 @default.
• W2938369148 cites W2050249255 @default.
• W2938369148 cites W2065799563 @default.
• W2938369148 cites W2096156234 @default.
• W2938369148 cites W2099530756 @default.
• W2938369148 cites W2103447891 @default.
• W2938369148 cites W2104830962 @default.
• W2938369148 cites W2119317963 @default.
• W2938369148 cites W2127841934 @default.
• W2938369148 cites W2130488043 @default.
• W2938369148 cites W2148332636 @default.
• W2938369148 cites W2150424194 @default.
• W2938369148 cites W2157687487 @default.
• W2938369148 cites W2301811958 @default.
• W2938369148 cites W2466915283 @default.
• W2938369148 cites W2586704604 @default.
• W2938369148 cites W2614720739 @default.
• W2938369148 cites W2624310346 @default.
• W2938369148 cites W2745391639 @default.
• W2938369148 cites W2748209653 @default.
• W2938369148 cites W2767072667 @default.
• W2938369148 cites W2775798067 @default.
• W2938369148 cites W2779968640 @default.
• W2938369148 cites W2794491531 @default.
• W2938369148 cites W2796923356 @default.
• W2938369148 cites W2800286167 @default.
• W2938369148 cites W2805911662 @default.
• W2938369148 cites W2885875860 @default.
• W2938369148 cites W2889170871 @default.
• W2938369148 doi "https://doi.org/10.1016/j.jtho.2019.03.020" @default.
• W2938369148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30978502" @default.
• W2938369148 hasPublicationYear "2019" @default.
• W2938369148 type Work @default.
• W2938369148 sameAs 2938369148 @default.
• W2938369148 citedByCount "67" @default.
• W2938369148 countsByYear W29383691482019 @default.
• W2938369148 countsByYear W29383691482020 @default.
• W2938369148 countsByYear W29383691482021 @default.
• W2938369148 countsByYear W29383691482022 @default.
• W2938369148 countsByYear W29383691482023 @default.
• W2938369148 crossrefType "journal-article" @default.
• W2938369148 hasAuthorship W2938369148A5000668683 @default.
• W2938369148 hasAuthorship W2938369148A5002306737 @default.
• W2938369148 hasAuthorship W2938369148A5006712577 @default.
• W2938369148 hasAuthorship W2938369148A5007155024 @default.
• W2938369148 hasAuthorship W2938369148A5008015466 @default.
• W2938369148 hasAuthorship W2938369148A5013884017 @default.
• W2938369148 hasAuthorship W2938369148A5014324672 @default.
• W2938369148 hasAuthorship W2938369148A5014839908 @default.
• W2938369148 hasAuthorship W2938369148A5016567527 @default.
• W2938369148 hasAuthorship W2938369148A5016904876 @default.

• next